JGC
SNTI icon

J. Goldman & Co’s Senti Biosciences Holdings SNTI Stock Holding History

J. Goldman & Co’s Portfolio SNTI Stock Details SNTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,000
Closed -$497K – 433
2021
Q3 		$497K Sell
5,000
-5,000
-50% -$493K 0.02% 274
2021
Q2 		$994K Buy
+10,000
New +$998K 0.04% 282

Other funds holding SNTI

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
TCA
Taconic Capital Advisors New York $229M AUM 110.07% 1-Year Est. Return

J. Goldman & Co's SNTI Position: Q4 2021 in Review

J. Goldman & Co sold out of Senti Biosciences Holdings (SNTI) in Q4 2021, closing a stake of 5,000 shares — an estimated $497K sold.

J. Goldman & Co first reported a position in SNTI in Q2 2021 and held it in 2 quarters. The position peaked at $994K in Q2 2021. 42 funds tracked by Wall St. Rank hold SNTI as of Q4 2021.

  • J. Goldman & Co reported no remaining Senti Biosciences Holdings position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 5,000 Senti Biosciences Holdings shares in Q4 2021, an estimated $497K.
  • J. Goldman & Co first reported a position in Senti Biosciences Holdings in Q2 2021 and held it in 2 quarters.
  • J. Goldman & Co's Senti Biosciences Holdings position peaked at $994K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.